Kenvue shares rebounded after a sharp fall triggered by Donald Trump’s unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity.